$HIMS is quietly positioning itself beyond just telehealth — peptides could be the next unlock.
From weight loss to recovery, longevity, and performance — peptide demand is exploding. And distribution + trust is everything here.
That’s where already has an edge:
- Massive DTC platform
- Existing patient base
- Strong brand in wellness
If they execute right, peptides aren’t just an add-on… they’re a margin + growth accelerator.
Telehealth was phase 1.
Personalized performance medicine could be phase 2.
$HIMS
🚨BREAKING: The closing of the " Strait of Hormuz" will have NO impact on the 3M+ subscribers of $HIMS .
HIMS runs on 3M+ recurring purchases , not global shipping lanes.
$HIMS to $100+ by 2030🚀
$SOFI is undervalued.
$AMD is undervalued.
$HIMS is undervalued.
$AMZN is undervalued.
$META is undervalued.
$NBIS is undervalued.
$ZETA is undervalued.
$IREN is undervalued.
$GRAB is undervalued.
$DLO is undervalued.
$OSCR is undervalued.
$SNAP is undervalued.
$ODD is undervalued.
🚨BREAKING: We have CLOSED our positions in $UNH with 8% PROFIT & in $JD with 12% LOSS.
Now, we are sitting on 25% CASH for DIP-BUYING in existing & New positions 🤠
Will share soon !
👀 5 stocks to buy and hold for the next decade
1. $DLO - DLocal
DLO is building the financial plumbing for emerging markets—one of the most underpenetrated yet fastest-growing segments in global fintech.
1. Picks & Shovels of EM Growth
Instead of betting on individual e-commerce winners, DLocal powers payments for global giants entering Latin America, Africa, and Asia. As cross-border commerce expands, DLO captures volume regardless of which platform wins.
2. High-Margin, Asset-Light Model
With no need for heavy lending or balance sheet risk, DLocal operates a scalable, high-margin payments infrastructure business—similar to early Adyen, but focused on harder-to-serve regions.
3. Strong Competitive Moat
Local regulatory complexity, fragmented payment methods, and FX challenges create high barriers to entry. Once integrated, merchants rarely switch—leading to strong retention and pricing power.
4. Operating Leverage Kicker
As volumes scale, costs don’t rise proportionally → expanding EBITDA margins over time.
5. Undervalued Growth Story
Despite strong revenue growth and profitability, DLO trades at a discount to global peers due to past concerns (governance, short reports). If sentiment normalizes, multiple expansion alone could drive upside.
⸻
Bottom Line:
DLO is a leveraged bet on the digitization of emerging markets—with sticky infrastructure, strong margins, and long runway for growth.